DelezenneCPozerskiE. Actiondue sèrum sanguin sur la gèlatine en prèsesnce do chloroforme. C R Soc Biol (Paris)1903; 55:327–329
2.
TillettWSSherryS. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal deoxyribonuclease on fibrinous, purulent, and sanguinous plural exudations. J Clin Invest1949; 28:173–190
3.
JohnsonAJTillettWS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med1952; 95:449–464
AgreesCMJacobsHIBinderMJ. Intravenous trypsin in experimental myocardial infarction. Circ Res1954; 2:397–404
6.
EhrlichHJBangNULittleSP. Biological properties of a kringleless tissue plasminogen activator (t-PA) mutant. J Fibrin1987; 1:75–81
7.
CollenDLuHRLijnenHR. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation1991; 84:1215–1234
8.
CollenDLijenHRVanlinthoutI. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. Thromb Haemost1991; 65:174–180
9.
JacksonCVCroweVGCraftTJ. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation1990; 82:930–940
10.
WuZVan de WerfFStassenT. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6–173) in a canine model. J Cardiovasc Pharmacol1990; 16:197–203
11.
AgnelliGPascucciCColucciM. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2 tu-pa) in rabbits. Thromb Haemost1992; 68:331–335
12.
CollenDDewerchinMRapoldHJ. Thrombolytic and pharmacokinetic properties of conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. Circulation1990; 82:1744–1754
13.
LuHRWuZPauwelsP. Comparative thrombolytic properties of tissue-type plasminogen activator (–PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined and venous thrombosis model in the dog. J Am Coll Cardiol1992; 19:1350–1359
14.
BushLRCampbellWBKernK. The effects of alpha2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res1984; 55:642–652
15.
GolinoPAshtonJGBujaM. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo: Thromboxane A2 and serotonin are possible mediators. Circulation1985; 79:154–166
16.
GolinoPAshtonJGGlas-GreenwaltP. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation1988; 77:678–684
17.
SheboskRJSmithJMStorerBL. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after t-PA-induced coronary thrombolysis. J Pharmacol Exp Ther1988; 246:790–796
18.
FitzgeraldDJWrightFFitzGeraldGA. Increased thromboxane biosynthesis during coronary thrombolysis: Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res1989; 65:83–94
19.
ShebuskiRJStorerBLFujitaT. Effect of thromboxane synthase inhibitor on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res1988; 52:381–392
20.
FitzgeraldDJKerinsDMFitzGeraldGA. Coronary reocclusion following therapeutic thrombolysis; prevention by thromboxane antagonism and thrombin inhibition (abstract). Clin Res1989; 37:257A
21.
GolinoPFocaccioAEidtJ. Iloprost reduces time to thrombolysis and alters reocclusion after t-PA in a canine model of thrombosis (abstract). Circulation1988; 78(suppl II): II–16
22.
TopolEJEllisSGCaliffRM. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol1989; 14:877–884
23.
KerinsDMFitzGeraldGAFitzgeraldDJ. Interactions of a prostacyclin analogue and tissue plasminogen activator (rt-PA) during coronary thrombolysis (abstract). Clin Res1989; 37:271A
VaughanDEPlavinSRSchaferAGLLoscalzoJ. PGE accelerates thrombolysis by tissue plasminogen activator. Blood1989; 73:1213–1217
26.
CollerBSFoltsJDSmithSR. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibody to the platelet GP (b/IIIa) receptor: Correlation with bleeding time, platelet aggregation and blockade of GP IIb/IIIa receptors. Circulation1989; 80:1766–1774
27.
MickelsonJKSimpsonPJCroninM. Antiplatelet antibody (7 E3 F (Ab1)2) prevents rethrombosis after recombinant tissue-type plasminogen activator induced coronary artery thrombolysis in a canine model. Circulation1990; 81:617–687
28.
BadimonLLassilaRBadimonJJ. Platelet deposition on severely damaged vessel wall at flow conditions typical of stenotic vessel is inhibited by LJ-CP3 (antiplatelet glycoprotein GPIIb/IIIa monoclonal antibody) (abstract). J Am Coll Cardiol1990; 15(suppl A): 188A
29.
HaskelEJAdamsSPFeigenLP. Prevention of reocclusion platelet rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation1989; 80:1775–1782
30.
StronyJPhillipsMBrandsD. Aurintricarboxylic acid in a canine model of coronary artery thrombosis. Circulation1990; 81:1106–1114
31.
HaskelEJTorrSRDayKC. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation1991; 84:821–827
32.
BagdyDSzabòGBarabàsÉBajuszS. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost1992; 68:125–129
33.
ImuraYStassenJVreysI. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost1992; 68:336–340
